FDA Identifies Deficiencies in Aquestive Therapeutics Drug Application
1 report, 1 independent
Updated Oct 7
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA identified deficiencies in the New Drug Application for Anaphylm, a drug candidate submitted by Aquestive Therapeutics. This news followed an announcement on January 9, 2026, that precluded discussions of labeling and post-marketing commitments. Following the announcement, Aquestive Therapeutics' stock price declined 37%. A securities class action complaint alleges that Aquestive misled investors about the prospects for FDA approval between June 2025 and January 2026.
From prnewswire.com
Why it matters
The deficiencies in the drug application and the subsequent legal claims regarding alleged false statements could impact investor confidence in Aquestive Therapeutics and affect the company's financial stability.
From prnewswire.com
Who's involved
- FDARegulatory agency that identified deficiencies in the drug application
Keep exploring
The entities involved
Related events
- The Charlotte Lozier Institute found that the FDA lacked sufficient evidence in its review process.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA provided guidance for HCW Biologics' IND application.
- FDA regulates drug shortages and systemic supply chain issues in the US.
- FDA approval enables commercial availability for a product associated with Indianapolis.